Perspectives in clinical gastroenterology and hepatologyManagement of Gastric Varices
Section snippets
Primary Prophylaxis
In a prospective study including 117 patients with cirrhosis and cardiofundal varices (69% IGV1 and 31% GOV2), the incidence of bleeding was 16%, 36%, and 44% at 1, 3, and 5 years, respectively. Size of varices, presence of red signs, and the degree of liver dysfunction were directly related with the risk of bleeding (ranging from an annual incidence of bleeding of 4% in patients with Child class A with small varices without red signs to 65% in patients with Child class C with large varices
Management of Acute Gastric Variceal Bleeding
Although no studies have been specifically devoted to address this issue in patients with cardiofundal varices, general consensus is that the initial management is similar to that of esophageal variceal bleeding, including the use of prophylactic antibiotics, careful replacement of volemia with a restrictive transfusion policy, and the early administration of vasoactive drugs (terlipressin, somatostatin, or a somatostatin analogue).4, 5 IGV1 varices, which often appear as a consequence of large
Secondary Prophylaxis
Rebleeding rates after an acute GV bleeding episode treated with tissue adhesives (mainly CA) range from 7%-65%, with most of the large series reporting rates below 15%. Thus, after initial hemostasis with tissue adhesives, repeated sessions are performed on a 2- to 4-week basis until endoscopic obliteration is achieved. Several case series and controlled studies have specifically evaluated the effect of long-term injections of tissue adhesives (mainly CA) to prevent GV rebleeding17, 25, 26, 27
Other Endoscopic Therapies
Other endoscopic treatments have also been used to prevent rebleeding. Sclerotherapy has been abandoned because of high rebleeding rates (50%-90%). Variceal band ligation may be used for those patients with GOV1 and in some cases of small GOV2, and it is generally performed every 2 weeks until apparent endoscopic obliteration. However, band ligation is limited by the fact that it cannot be used in large GOV2 or IGV1.7 Detachable loop snares to treat large GV (>2 cm) along with propranolol have
Thrombin
Thrombin converts fibrinogen to a fibrin clot, thus forming a clot inside the GV and occluding blood flow. The use of bovine thrombin was banned because of the risk of potential prion transmission. This is not the case when using commercially available human thrombin. Each vial is reconstituted with 5 mL distilled water for a concentration of 250 U/mL.35 The average dose of injected thrombin ranges between 1500 and 2000 U. Available data indicate that thrombin is safe and effective in the
Transjugular Intrahepatic Portosystemic Shunt
The role of TIPS vs CA in preventing GV bleeding has been evaluated in 3 small studies (2 retrospective observational studies and 1 prospective). Remarkably, in all 3 studies most patients included had GOV1, a few GOV2, and only anecdotal IGV1 varices. In addition, the stents used were uncoated, which has been shown to be associated with lower TIPS patency, efficacy, and survival than coated stents.42 Two of these studies23, 43 showed a higher rebleeding rate in the CA group (30% and 59%) vs
Surgery
Surgery has currently fallen out of favor for patients with portal hypertension because of the wide availability of less invasive techniques such as endoscopy and interventional radiology. In selected cases, patients with GV and segmental/left-sided portal hypertension that is due to isolated splenic vein thrombosis may be candidates for splenectomy or splenic embolization as a means of definitive therapy; however, data are scarce.
Balloon-occluded Retrograde Transvenous Obliteration
Balloon-occluded retrograde transvenous obliteration (BRTO) has been introduced as a treatment method that aims to directly obliterate the GV. Since its introduction by Kanagawa et al,45 BRTO has become widely accepted in Japan and in some centers in the United States as a minimally invasive and highly effective treatment for GV. The technical difficulty of BRTO relies on the anatomy of the afferent and draining veins of the GV. Accurate assessment, which is mainly based on imaging studies of
Summary
The best management strategy for GV has not been completely established because of a paucity of data of RCTs in this area. Specific treatments such as CA injection and BRTO are not widely available in all centers. Another limitation is the fact that tissue adhesives such as CA are not approved by the Food and Drug Administration in the United States, and thus, recommendations arising from published studies, guidelines, and expert opinion cannot be extrapolated to routine practice. We recommend
References (77)
- et al.
Risk factors for hemorrhage from gastric fundal varices
Hepatology
(1997) - et al.
Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial
J Hepatol
(2011) Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension
J Hepatol
(2010)- et al.
A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices
Hepatology
(2001) - et al.
A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices
Am J Gastroenterol
(2002) - et al.
Should GOV1 be treated as for esophageal varices?
Gastroenterology
(2004) - et al.
N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis
Am J Gastroenterol
(2003) - et al.
A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos)
Gastrointest Endosc
(2008) - et al.
Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate
Clin Gastroenterol Hepatol
(2010) - et al.
Esophageal tamponade for bleeding varices: controlled trial between the Sengstaken-Blakemore tube and the Linton-Nachlas tube
Gastroenterology
(1978)
"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding
Gastroenterology
Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis
J Hepatol
Cost-effectiveness of N-butyl-2-cyanoacrylate (histoacryl) glue injections versus transjugular intrahepatic portosystemic shunt in the management of acute gastric variceal bleeding
Am J Gastroenterol
EUS-guided transesophageal treatment of gastric fundal varices with combined coiling and cyanoacrylate glue injection (with videos)
Gastrointest Endosc
Efficacy of non-selective beta-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial
J Hepatol
The use of thrombin injections in the management of bleeding gastric varices: a single-center experience
Gastrointest Endosc
An open pilot study of the effects of a human fibrin glue for endoscopic treatment of patients with acute bleeding from gastric varices
Gastrointest Endosc
Endoscopic use of human thrombin in bleeding gastric varices
Am J Gastroenterol
Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center US analysis
Gastrointest Endosc
Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy
J Vasc Interv Radiol
Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam
J Vasc Interv Radiol
Pre- and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging: indications, management protocols, and follow-up
Tech Vasc Interv Radiol
Endoscopic treatment of bleeding gastric varices by N-butyl-2- cyanoacrylate (Histoacryl) injection: long-term efficacy and safety
Gastrointest Endosc
Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding: a 10-year experience
Surgery
A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans
Gastrointest Endosc
A randomized trial of endoscopic cyanoacrylate injection for acute gastric variceal bleeding: 0.5 mL versus 1.0 mL
Gastrointest Endosc
Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients
Hepatology
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
Hepatology
Prognosis of acute bleeding from isolated fundal varices in patients with cirrhosis: a European cohort
Hepatology
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation
Hepatology
Ethanolamine oleate versus butyl cyanoacrylate for bleeding gastric varices: a nonrandomized study
Endoscopy
Enbucrilate for gastric varices: extended experience in 92 patients
Aliment Pharmacol Ther
Study of glue extrusion after endoscopic N-butyl-2-cyanoacrylate injection on gastric variceal bleeding
World J Gastroenterol
[Long-term results of endoscopic histoacryl (N-butyl-2-cyanoacrylate) injection for treatment of gastric varices: a 10-year experience]
Korean J Gastroenterol
Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization
Hepatol Int
Comparison of transjugular intrahepatic portosystemic shunt (TIPS) alone versus TIPS combined with embolotherapy in advanced cirrhosis: a retrospective study
J Clin Gastroenterol
Early use of TIPS in patients with cirrhosis and variceal bleeding
N Engl J Med
Long-term follow-up of endoscopic Histoacryl glue injection for the management of gastric variceal bleeding
QJM
Cited by (114)
Challenges in the Management of Esophagogastric Varices and Variceal Hemorrhage in Cirrhosis – A Narrative Review
2024, American Journal of MedicineRole of endoscopy in hepatology
2024, Digestive and Liver DiseaseEndoscopic procedures in hepatology: Current trends and new developments
2024, Journal of HepatologyThe use of endoscopic ultrasound in the diagnosis and management of portal hypertension
2022, Best Practice and Research: Clinical GastroenterologyTransjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial
2022, The Lancet Gastroenterology and HepatologyCitation Excerpt :However, our results showed that there was no interaction between the location of the varices and treatment group. A possible explanation might be that the most common gastric varices in our cohort were gastroesophageal varices type 1, a continuation of oesophageal varices into the lesser curvature of the stomach, in which gastrorenal and portosystemic shunts are less common.39 Other patients, such as those with continued variceal filling despite a patent shunt and those with large calibre submucosal vessels, might have a high-risk of rebleeding after TIPS and might benefit from embolisation.17
This article has an accompanying continuing medical education activity on page e52. Learning Objectives-At the end of this activity, the successful learner will understand the prevalence, classification, and therapy of gastric varices in patients with cirrhosis.
Conflicts of interest These authors disclose the following: Juan Garcia-Pagán received grant support from GORE. Andres Cardenas has been a consultant to Limmedx LLC, Frontier Medex, and BMJ Publishing Group. The remaining authors disclose no conflicts.